Nasdaq Inc. reported stronger-than-expected fourth-quarter results, fueled by surging revenue from its technology solutions division and strategic AI initiatives, even as the company navigates a tighter margin environment.
The parent company of numerous restaurant chains will be removed from the Nasdaq exchange on February 4, transitioning to high-risk over-the-counter trading after failing to meet listing requirements.
As a profitable outlier in a battered sector, Ethos Technologies' successful IPO marks a pivotal test for investor appetite in 2026's tech listings, even as its debut valuation reflects a more sober market reality.
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.
While Automatic Data Processing (NASDAQ:ADP) has delivered solid earnings growth over five years, its share price appreciation has notably lagged the broader market. A deeper look reveals dividends have bolstered total returns, but recent underperformance highlights investor caution toward the payroll giant.
While passive index funds track the broader market, selective stock picks can deliver outsized returns. Baidu's (NASDAQ: BIDU) shares have soared 75% in the past year, dramatically outpacing the market. This rally comes despite a significant drop in earnings, shifting investor focus towards the company's long-term strategic bets in artificial intelligence and autonomous driving.
Despite modest revenue growth and lack of profitability, Cognyte Software (NASDAQ: CGNT) has delivered a remarkable 133% return to shareholders over the past three years, highlighting a stark divergence between financial fundamentals and market optimism.
Despite a brutal 50% share price plunge over three months, Reitar Logtech Holdings (NASDAQ:RITR) exhibits underlying financial resilience. While its Return on Equity appears weak, the company's aggressive reinvestment strategy has fueled a remarkable 26% net income growth over five years, starkly outperforming its struggling industry. This analysis delves into the disconnect between short-term market sentiment and the firm's long-term operational engine.
A staggering 2,313% surge in Elong Power Holding's (NASDAQ: ELPW) share price last week delivered a massive payoff for its largest shareholder group—private equity firms. With concentrated ownership and scant analyst coverage, the stock's dramatic move highlights both its potential and the risks inherent in such thinly followed names.
Bassett Furniture Industries (NASDAQ: BSET) has seen significant price swings in recent months, drawing investor scrutiny. With a current trading price well below its calculated intrinsic value and a bullish earnings forecast, analysts are debating whether this small-cap furniture maker presents a timely buying opportunity.
While passive index funds mirror the broader market, selecting individual winners can dramatically boost returns. Citi Trends (NASDAQ: CTRN) shares have surged 77% over the past year, far exceeding the market's 14% gain, as investors bet on a potential revival despite ongoing profitability challenges.
While recent performance has moderated, Mercantile Bank Corporation (NASDAQ:MBWM) has rewarded long-term investors with a total shareholder return more than double the broader market's gains over the past half-decade, driven by consistent earnings growth and dividends.
A deep dive into the shareholder structure of Marten Transport, Ltd. (NASDAQ:MRTN) reveals a landscape dominated by institutional investors, whose collective actions can significantly sway the stock's trajectory. With the CEO also holding a substantial stake, we examine the balance of power and what it means for the company's future.
CECO Environmental Corp. (NASDAQ: CECO) has surged in recent months, nearing its yearly high. With the mid-cap clean tech firm now trading near fair value, we analyze whether investors have missed the bargain window or if strategic entry points remain.
While index funds offer market-average returns, picking the right stock can yield significantly more. Itron, Inc. (NASDAQ: ITRI) has proven just that, delivering a 71% return to shareholders over the past three years—outperforming broader indices—as it transitioned to profitability. However, recent headwinds have tempered the rally, raising questions about its near-term trajectory.
The UK pharmaceutical giant AstraZeneca begins trading ordinary shares on the New York Stock Exchange today, a significant upgrade from its previous Nasdaq ADR listing. This move underscores the company's strategic rebalancing towards the United States, its largest market, and raises questions about the long-term relevance of its London listing.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
Cardiac monitoring specialist iRhythm has finalized a significant corporate restructuring, creating a new parent company to serve as its publicly listed entity on Nasdaq. The move is seen as a strategic step to streamline governance and provide operational flexibility as the company expands its AI-driven health platform.
The Marzetti Company (NASDAQ:MZTI) is set to report fourth-quarter earnings before Tuesday's market open. Investors will scrutinize whether the maker of dressings and sauces can maintain its recent revenue beats amid a projected slowdown in growth and persistent margin pressures.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
